Logo image of CRDF

CARDIFF ONCOLOGY INC (CRDF) Stock Price, Quote, News and Overview

NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock - Currency: USD

3.62  0 (0%)

After market: 3.659 +0.04 (+1.08%)

CRDF Quote, Performance and Key Statistics

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (6/5/2025, 6:36:19 PM)

After market: 3.659 +0.04 (+1.08%)

3.62

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.64
52 Week Low2.01
Market Cap240.84M
Shares66.53M
Float62.20M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO07-27 2004-07-27


CRDF short term performance overview.The bars show the price performance of CRDF in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

CRDF long term performance overview.The bars show the price performance of CRDF in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100

The current stock price of CRDF is 3.62 USD. In the past month the price increased by 45.38%. In the past year, price increased by 23.55%.

CARDIFF ONCOLOGY INC / CRDF Daily stock chart

CRDF Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.25 331.15B
AMGN AMGEN INC 13.83 154.38B
GILD GILEAD SCIENCES INC 14.27 137.40B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.97B
REGN REGENERON PHARMACEUTICALS 10.9 52.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.16B
ARGX ARGENX SE - ADR 100.97 35.45B
ONC BEONE MEDICINES LTD-ADR 6.58 27.78B
BNTX BIONTECH SE-ADR N/A 26.48B
NTRA NATERA INC N/A 22.60B
BIIB BIOGEN INC 8.24 19.10B
SMMT SUMMIT THERAPEUTICS INC N/A 14.65B

About CRDF

Company Profile

CRDF logo image Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Company Info

CARDIFF ONCOLOGY INC

11055 Flintkote Ave

San Diego CALIFORNIA 92121 US

CEO: Mark Erlander

Employees: 32

CRDF Company Website

CRDF Investor Relations

Phone: 18589527570

CARDIFF ONCOLOGY INC / CRDF FAQ

What is the stock price of CARDIFF ONCOLOGY INC today?

The current stock price of CRDF is 3.62 USD.


What is the ticker symbol for CARDIFF ONCOLOGY INC stock?

The exchange symbol of CARDIFF ONCOLOGY INC is CRDF and it is listed on the Nasdaq exchange.


On which exchange is CRDF stock listed?

CRDF stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CARDIFF ONCOLOGY INC stock?

13 analysts have analysed CRDF and the average price target is 14.48 USD. This implies a price increase of 300.11% is expected in the next year compared to the current price of 3.62. Check the CARDIFF ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CARDIFF ONCOLOGY INC worth?

CARDIFF ONCOLOGY INC (CRDF) has a market capitalization of 240.84M USD. This makes CRDF a Micro Cap stock.


How many employees does CARDIFF ONCOLOGY INC have?

CARDIFF ONCOLOGY INC (CRDF) currently has 32 employees.


What are the support and resistance levels for CARDIFF ONCOLOGY INC (CRDF) stock?

CARDIFF ONCOLOGY INC (CRDF) has a support level at 2.63 and a resistance level at 3.63. Check the full technical report for a detailed analysis of CRDF support and resistance levels.


Is CARDIFF ONCOLOGY INC (CRDF) expected to grow?

The Revenue of CARDIFF ONCOLOGY INC (CRDF) is expected to decline by -47.11% in the next year. Check the estimates tab for more information on the CRDF EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CARDIFF ONCOLOGY INC (CRDF) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CARDIFF ONCOLOGY INC (CRDF) stock pay dividends?

CRDF does not pay a dividend.


When does CARDIFF ONCOLOGY INC (CRDF) report earnings?

CARDIFF ONCOLOGY INC (CRDF) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of CARDIFF ONCOLOGY INC (CRDF)?

CARDIFF ONCOLOGY INC (CRDF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).


What is the Short Interest ratio of CARDIFF ONCOLOGY INC (CRDF) stock?

The outstanding short interest for CARDIFF ONCOLOGY INC (CRDF) is 28.17% of its float. Check the ownership tab for more information on the CRDF short interest.


CRDF Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to CRDF. When comparing the yearly performance of all stocks, CRDF is one of the better performing stocks in the market, outperforming 73.55% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CRDF Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CRDF. While CRDF has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRDF Financial Highlights

Over the last trailing twelve months CRDF reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS decreased by -3.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.63%
ROE -68.96%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%9.09%
Sales Q2Q%-46.83%
EPS 1Y (TTM)-3.33%
Revenue 1Y (TTM)-3.76%

CRDF Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CRDF. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 15.33% and a revenue growth -47.11% for CRDF


Ownership
Inst Owners36.86%
Ins Owners1.99%
Short Float %28.17%
Short Ratio14.92
Analysts
Analysts83.08
Price Target14.48 (300%)
EPS Next Y15.33%
Revenue Next Year-47.11%